Ventaris Surgical, Inc., a San Carlos, CA-based medical device company developing a next-generation system for kidney stone treatment, announced  the completion of a $30 million Series A financing.

The financing was led by Longitude Capital, with additional participation from new investor Vensana Capital and existing investors Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners. As part of this financing, Varun Gupta of Longitude Capital and Justin Klein of Vensana Capital will join the Ventaris Board of Directors, alongside independent board member Amir Abolfathi.

Ventaris Surgical is developing a ureteroscopic system designed to help surgeons achieve more complete stone clearance during kidney stone procedures. Kidney stone surgery is among the most common urologic interventions, yet procedural success is influenced by a complex set of variables including anatomy, stone burden, workflow constraints, and surgeon fatigue. This makes consistent, complete stone clearance difficult to achieve with today's tools.

"Ventaris' technology has the potential to both improve outcomes and reduce the burden on surgeons. Their approach resolves several critical unmet needs in today's standard of care," said Maxwell Bikoff, Managing Director at Longitude Capital.

"Kidney stone surgery demands an exceptional level of skill, focus, and persistence," said Surag Mantri, CEO of Ventaris Surgical. "Surgeons are often willing to invest the time and effort required to pursue complete stone clearance, but today's tools can make that goal difficult to achieve consistently. Ventaris was founded with the goal of removing unnecessary friction from the procedure, so that surgeons can focus their time and effort on reliably achieving complete stone clearance. We are excited to embark on this next phase of growth with Longitude Capital and Vensana Capital."

Proceeds from this financing will be used to support continued clinical development and advancement of regulatory and commercial milestones.